Last updated on March 2019

Mucopolysaccharidosis I (MPS I) Registry


Brief description of study

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.

The objectives of the Registry are:

  • To evaluate the long-term effectiveness and safety of Aldurazyme (laronidase)
  • To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
  • To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care

Detailed Study Description

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:

Clinical Study Identifier: NCT00144794

Contact Investigators or Research Sites near you

Start Over

Investigational Site Number 458001

Jalan Pahang, Malaysia
4.65miles
  Connect »

Investigational Site Number 458002

Kuala Lumpur, Malaysia
6.68miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.